作用可能な薬理遺伝学的バリアントの数と入院期間との関連

Association Between Number of Actionable Pharmacogenetic Variants and Length of Hospital Stay.

• Joseph Finkelstein
• Frederick Zhang
• Manuel Cabrera

抄録

本研究の目的は，薬理遺伝学的変異体の数と入院期間の長さとの関連を評価することであった．入院患者450人を対象に、電子カルテとエクソームシークエンシングの結果を組み合わせた。非同定データセットを使用して、緊急ケアの利用状況を特徴付け、Clinical Pharmacogenetics Implementation Consortiumのガイドラインに従って44の作用可能な薬理遺伝学的変異体の存在を同定した。平均年齢は58.03±16.47で20歳から91歳まで、薬理遺伝学的変異体の平均数は61.22±26.52で20歳から169歳まで、平均在院日数は6.50±4.29で1日から42日であった。患者の社会統計学およびCharlson併存疾患指数によって反映される全疾患の重症度を調整した後、一般化線形回帰を用いて平均在院期間と薬理遺伝学的変異体の数との間に有意な関連が認められた（p値<2.2e-16）。

The goal of this study was to evaluate association between number of pharmacogenetic variants and length of hospital stay. Electronic medical records were combined with exome sequencing results in 450 hospitalized patients. De-identified data set was used to characterize urgent care utilization and to identify presence of 44 actionable pharmacogenetic variants according to the guidelines of the Clinical Pharmacogenetics Implementation Consortium. The average age was 58.03 ± 16.47 ranging from 20 to 91 years old, average number of pharmacogenetic variants was 61.22 ± 26.52 ranging from 20 to 169, and mean length of hospital stay was 6.50 ± 4.29 ranging between 1 and 42 days. After adjusting for patient socio-demographics and overall disease severity reflected by the Charlson comorbidity index, a significant association between mean length of stay and number of pharmacogenetic variants was found using generalized linear regression (p-value < 2.2e-16).